A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology

Volumn 134, Issue 2, 2014, Pages 262-266

  Eisenhauer, Eric L ^a   Zanagnolo, Vanna ^b   Cohn, David E ^a   Salani, Ritu ^a   O'Malley, David M ^a   Sutton, Gregory ^c   Callahan, Michael J ^c   Cobb, Bobbi ^a   Fowler, Jeffrey M ^a   Copeland, Larry J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c St Vincent Indianapolis Hospital   (United States)

Author keywords

Bevacizumab; Chemotherapy; Gemcitabine; Ovarian cancer; Platinum sensitive; Recurrent

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PLATINUM SENSITIVE RECURRENT OVARIAN CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA;

BEVACIZUMAB; CHEMOTHERAPY; GEMCITABINE; OVARIAN CANCER; PLATINUM-SENSITIVE; RECURRENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 84905590135     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.05.030     Document Type: Article

References (24)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
3. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
4. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707
5. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P.A. Vasey et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
6. G.J. Peters, A.M. Bergman, V.W. Ruiz van Haperen, G. Veerman, C.M. Kuiper, and B.J. Braakhuis Interaction between cisplatin and gemcitabine in vitro and in vivo Semin Oncol 22 1995 72 79
7. G. Rose, K. Mossbruger, N. Fusco, M. Smrekar, S. Eaton, and M. Rodriguez Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma Gynecol Oncol 88 2003 17 21
8. R.A. Nagourney, C.A. Brewer, S. Radecki, W.A. Kidder, B.L. Sommers, and S.S. Evans et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients Gynecol Oncol 88 2003 35 39
9. J. Folkman, K. Watson, D. Ingber, and D. Hanahan Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 61
10. G. Ranieri, R. Patruno, E. Ruggieri, S. Montemurro, P. Valerio, and D. Ribatti Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 13 2006 1845 1857
11. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
12. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.L. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
13. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
14. R.I.J. Arca, G. Lerzo, M. Mandachain, E. Mickievicz, and J. Perez et al. Gemcitabine (GEM) + oxaliplatin (OX) in patients with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): preliminary report of a phase II study ASCO Annual Meeting J Clin Oncol 22 2004 5111
15. D. Germano, D. Bilancia, A. Di Nota, A.M. Dello Russo, R. Romano, and G. Rosati et al. Biweekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatinum pretreated patients with relapsed ovarian cancer (roc): preliminary data of a phase II trial ASCO Annual Meeting Abstract J Clin Oncol 22 2004 5104
16. R. Wilkowski, M. Thoma, E. Dühmke, H.G. Rau, and V. Heinemann Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma Int J Radiat Oncol Biol Phys 58 2004 768 772
17. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
18. G.C. Stuart, H. Kitchener, M. Bacon, A. du Bois, M. Friedlander, and J. Ledermann et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21 2011 750 755
19. C.J. van Moorsel, H.M. Pinedo, G. Veerman, A.M. Bergman, C.M. Kuiper, and J.B. Vermorken et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br J Cancer 80 1999 981 990
20. D. Tewari, B.J. Monk, M. Hunter, C.A. Falkner, and R.A. Burger Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma Invest New Drugs 22 2004 475 480
21. C.A. Brewer, J.A. Blessing, R.A. Nagourney, M. Morgan, and P. Hanjani Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group Gynecol Oncol 103 2006 446 450
22. G. Bozas, A. Bamias, V. Koutsoukou, E. Efstathiou, D. Gika, and C.A. Papadimitriou et al. Biweekly gemcitabine and cisplatin in platinum-resistant/ refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma Gynecol Oncol 104 2007 580 585
23. J.A. Ledermann, H. Gabra, G.C. Jayson, V.J. Spanswick, G.J. Rustin, and M. Jitlal et al. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer Clin Cancer Res 16 2010 4899 4905
24. R.D. Alvarez, R. Mannel, A.A. Garcia, H.H. Gallion, J. Lucci 3rd, and L.C. Kilgore et al. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study Gynecol Oncol 115 2009 389 395